Arizona PSPRS Trust Purchases New Holdings in Replimune Group, Inc. (NASDAQ:REPL)

Arizona PSPRS Trust acquired a new position in Replimune Group, Inc. (NASDAQ:REPL) during the third quarter, Holdings Channel.com reports. The institutional investor acquired 76,100 shares of the company’s stock, valued at approximately $834,000.

Several other institutional investors have also added to or reduced their stakes in REPL. Baker BROS. Advisors LP grew its holdings in shares of Replimune Group by 10.0% in the third quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company’s stock worth $121,057,000 after purchasing an additional 1,000,000 shares during the last quarter. Erste Asset Management GmbH purchased a new stake in Replimune Group in the 3rd quarter valued at about $133,000. Braidwell LP increased its position in shares of Replimune Group by 203.0% during the third quarter. Braidwell LP now owns 3,070,837 shares of the company’s stock worth $33,656,000 after acquiring an additional 2,057,460 shares during the period. MetLife Investment Management LLC increased its position in shares of Replimune Group by 21.5% during the third quarter. MetLife Investment Management LLC now owns 35,134 shares of the company’s stock worth $385,000 after acquiring an additional 6,216 shares during the period. Finally, BNP Paribas Financial Markets boosted its holdings in shares of Replimune Group by 81.7% in the third quarter. BNP Paribas Financial Markets now owns 15,011 shares of the company’s stock valued at $165,000 after purchasing an additional 6,748 shares during the period. Institutional investors own 92.53% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on REPL. JPMorgan Chase & Co. raised their price objective on Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, September 24th. Roth Mkm assumed coverage on Replimune Group in a research note on Tuesday, August 27th. They set a “buy” rating and a $17.00 price target on the stock. HC Wainwright reissued a “buy” rating and set a $17.00 target price on shares of Replimune Group in a research report on Friday, November 22nd. BMO Capital Markets increased their price objective on shares of Replimune Group from $14.00 to $18.00 and gave the company an “outperform” rating in a research note on Friday, November 22nd. Finally, Roth Capital upgraded Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Replimune Group presently has a consensus rating of “Buy” and an average target price of $17.00.

Replimune Group Price Performance

Shares of NASDAQ REPL opened at $14.08 on Monday. Replimune Group, Inc. has a fifty-two week low of $4.92 and a fifty-two week high of $17.00. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11. The company has a market cap of $963.35 million, a PE ratio of -4.62 and a beta of 1.19. The business has a 50-day simple moving average of $11.89 and a two-hundred day simple moving average of $10.02.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.07. As a group, equities analysts expect that Replimune Group, Inc. will post -2.99 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Konstantinos Xynos sold 7,246 shares of the firm’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $10.78, for a total transaction of $78,111.88. Following the completion of the transaction, the insider now owns 109,885 shares of the company’s stock, valued at $1,184,560.30. This trade represents a 6.19 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 8.80% of the stock is owned by corporate insiders.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.